Healthcare Equipment and Supplies
Company Overview of Bioness Inc.
Bioness Inc. designs, develops, and distributes medical devices for people with stroke, multiple sclerosis, traumatic brain injury, cerebral palsy, and spinal cord injury. The company’s products use functional electrical stimulation to help people regain mobility and independence to improve quality of life and productivity. It offers L300, a foot drop system for people with various neurological conditions that enables to walk naturally, with increased speed and improved balance. The company also provides L300 Plus for foot drop and thigh weakness, which delivers programmed, low-level electrical stimulation to activate the nerves controlling the muscles of the leg. In addition, it offers H200...
25103 Rye Canyon Loop
Valencia, CA 91355
Founded in 2004
Key Executives for Bioness Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2014.
Bioness Inc. Key Developments
Bioness, Inc. Launches Bioness Integrated Therapy System (BITS(TM))
Oct 7 14
Bioness Inc. announced the launch of the Bioness Integrated Therapy System (BITS(TM)), a touch-screen based clinical rehabilitation platform designed to evaluate and improve abilities for individuals with disabilities resulting from traumatic injuries and neurological disorders and to improve performance in competitive athletes. BITS is a clinical nexus that allows current and future Bioness technologies to be integrated on a single platform. The system consists of a touchscreen display (up to 65") mounted on a highly portable stand and is designed to support a series of software programs for optimizing patient outcomes. The system is being launched with a Visuomotor software program covering seven main therapy categories including eye-hand, rotator, rapid eye movement, memory recall, metronome, letter chart and visual-motor programs. These therapy categories provide unique programs for visual-motor integration, improving reaction time, improving visual and auditory memory, visual-vestibular integration and improving hand speed and field attention.
Bioness, Inc. Announces 42-Week Follow Up Results from Functional Ambulation
Feb 3 14
Bioness, Inc. announced that 42-week follow-up results from the company's Functional Ambulation: Standard Treatment vs. Electrical Stimulation Therapy (FASTEST) trial of the Bioness L300(R) Foot Drop System have been published in the American Academy of Physical Medicine and Rehabilitation's journal, PM&R. The study, titled "Response and Prediction of Improvement in Gait Speed from Functional Electrical Stimulation in Post-Stroke Drop Foot," is an extension of the primary 30-week analysis demonstrating a similar impact with greater satisfaction when the L300 was compared to an ankle foot orthosis (AFO). Focusing on the participants randomized to the L300 group, the latest results published in PM&R demonstrate that persons with drop foot following stroke continued to show clinically meaningful and statically significant improvement in gait speed using the Bioness L300 up to 42 weeks. As a whole, the group experienced an immediate increase of walking speed of 19% which continued to improve to 33.3% at 30 weeks as compared to baseline. This progressed to 45.0% improvement at the end of 42 weeks.
Bioness, Inc. Appoints Todd Cushman as President and CEO
Sep 25 13
Bioness Inc. announced that its Board of Directors has named Todd Cushman as the company's President and CEO in an effort to refine its strategy and reorganize the company's core operations to better support its strategic growth opportunities. Cushman has been involved in the Bioness business since 2004, when he joined as Vice President of Business Development. Since that time, Cushman has held several critical roles within the company, most recently serving as Chief Commercial Officer. As CEO, Cushman will lead company's efforts to work with providers to improve access to the Bioness devices, among other strategic objectives.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|